NOZZOLILLO, AGOSTINO
 Distribuzione geografica
Continente #
NA - Nord America 110
AS - Asia 63
EU - Europa 56
AF - Africa 7
SA - Sud America 2
Totale 238
Nazione #
US - Stati Uniti d'America 110
SG - Singapore 34
IT - Italia 27
HK - Hong Kong 20
CI - Costa d'Avorio 7
RU - Federazione Russa 7
GB - Regno Unito 6
NL - Olanda 5
DE - Germania 4
VN - Vietnam 4
FI - Finlandia 3
IN - India 3
AT - Austria 2
BR - Brasile 2
CN - Cina 2
BE - Belgio 1
IE - Irlanda 1
Totale 238
Città #
Santa Clara 22
Singapore 21
Hong Kong 20
Ashburn 10
Chandler 10
Lawrence 5
Millbury 5
Naples 5
Amsterdam 4
Boston 4
Des Moines 4
Dong Ket 4
Afragola 2
Basildon 2
Dallas 2
Grottaferrata 2
Lappeenranta 2
Redhill 2
Rome 2
Vienna 2
Wilmington 2
Beijing 1
Brussels 1
Campo San Martino 1
Catania 1
Cerrione 1
Dublin 1
Fairfield 1
Falkenstein 1
Frankfurt am Main 1
Fremont 1
Goiânia 1
Helsinki 1
Los Angeles 1
Milan 1
Moscow 1
Munich 1
Napoli 1
Palermo 1
Perugia 1
Pune 1
San Sebastiano Al Vesuvio 1
São Paulo 1
Torre del Greco 1
Totale 155
Nome #
COVID-19 pandemic and mental distress in Multiple Sclerosis: implications for clinical management 43
Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience 37
Perampanel Confirms to Be Effective and Well-Tolerated as an Add-On Treatment in Patients With Brain Tumor-Related Epilepsy (PERADET Study) 32
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis 31
Incidence and predictive risk factors of infective events in patients with multiple sclerosis treated with agents targeting CD20 and CD52 surface antigens 30
Signs and symptoms of COVID-19 in patients with multiple sclerosis 27
Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials 20
Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors 18
Sexual dysfunction in people with multiple sclerosis: The role of disease severity, illness perception, and depression 17
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study 7
Totale 262
Categoria #
all - tutte 1.697
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.697


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206 0 0 0 0 0 0 0 0 0 4 1 1
2020/20218 0 0 0 3 1 0 0 0 0 0 0 4
2021/202235 1 0 0 3 0 2 0 1 1 7 7 13
2022/202345 5 2 1 0 3 7 1 4 13 6 3 0
2023/202450 1 9 1 2 2 6 6 7 1 2 6 7
2024/2025118 10 15 1 3 13 24 36 16 0 0 0 0
Totale 262